What's New And What's Next In CAR-T After ASH
Executive Summary
Incremental updates at the recent ASH meeting shed light on which products may follow Novartis' Kymriah and Gilead/Kite's Yescarta into the commercial market. Will it be Celgene and Bluebird or Celgene and Juno? Where do Pfizer, Servier and Cellectis stand with their off-the-shelf options?
You may also be interested in...
Keeping Track: We're Back!
The latest drug development news and highlights from our US FDA Performance Tracker.
Scrip Company Of The Year Celgene In Rude Health Despite Hiccups
Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.